Sarepta Therapeutics stock (US8036071004): focus on valuation as gene therapy franchise develops

Sarepta Therapeutics shares remain in focus on the Nasdaq as investors weigh the valuation of its Elevidys gene therapy franchise and broader pipeline in the United States market.

Sarepta Therapeutics trades on the Nasdaq under the ticker SRPT as a United States biotechnology stock focused on genetic medicines, with investors closely tracking how the market values its Elevidys gene therapy for Duchenne muscular dystrophy and other RNA and gene therapy candidates. As a mid-cap US biotech name, the company is regularly referenced in discussions about accelerated approval, particularly after Elevidys received US Food and Drug Administration clearance under the accelerated approval pathway in 2023, putting the stock in the spotlight for US healthcare and biotech portfolios.

The stock continues to trade on Nasdaq in US dollars as part of the US biotechnology universe, and it is frequently used as a case study in the broader debate over the FDA’s accelerated approval framework for rare disease treatments. For German-based investors, SRPT can typically be accessed via secondary trading venues such as Tradegate or Frankfurt in euros, although the primary price discovery and liquidity remain firmly centered on the Nasdaq listing in the United States.

As of: 05/29/2026

By the editorial team - specialized in equity coverage.

At a glance

• Name: SRPT
• Sector/industry: Biotechnology - genetic medicines
• Headquarters/country: Cambridge, United States
• Core markets: United States and global rare disease markets
• Key revenue drivers: Genetic therapies for neuromuscular and rare diseases, including Duchenne muscular dystrophy treatments such as Elevidys, plus RNA and gene therapy candidates
• Home exchange/listing venue: Nasdaq (SRPT)
• Trading currency: USD

Sarepta Therapeutics: core business model

Sarepta Therapeutics concentrates on developing and commercializing genetic medicines, with revenue primarily tied to therapies for Duchenne muscular dystrophy and other rare neuromuscular conditions, alongside a pipeline of RNA and gene therapy programs.

Valuation metrics and multiples for Sarepta Therapeutics

For investors on the Nasdaq in the United States, Sarepta Therapeutics is typically assessed using growth-oriented biotechnology valuation measures rather than traditional earnings-based ratios, because cash flows are heavily influenced by R&D spending on its gene therapy and RNA platforms. Historical discussions around Elevidys illustrate how much value the market assigns to potential peak sales and label expansions in Duchenne muscular dystrophy, while also discounting regulatory and reimbursement risks associated with therapies that entered the market via the FDA’s accelerated approval process.

Within the US biotech peer group, Sarepta Therapeutics is often compared with other rare disease and gene therapy developers, and investors monitor valuation against factors such as clinical trial progress, regulatory feedback, and commercialization milestones for its lead programs. The share price on Nasdaq therefore tends to embed expectations for the trajectory of Elevidys in the United States and internationally, as well as the potential for additional approvals across its broader portfolio of genetic medicines.

Conclusion

Sarepta Therapeutics remains an actively traded US biotechnology stock on Nasdaq, and its valuation continues to be shaped by market expectations for the Elevidys gene therapy franchise and the success of its wider genetic medicine pipeline. For investors evaluating SRPT, the key questions revolve around how regulators, payers and physicians will respond to gene therapies for Duchenne muscular dystrophy, and how this response will translate into long-term revenue and cash-flow potential reflected in the share price.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.